Teva Canada intros generic Concerta

Press enter to search
Close search
Open Menu

Teva Canada intros generic Concerta

By David Salazar - 03/22/2018
Teva Canada has launched its generic Concerta (methylphenidate hydrochloride). The extended-release tablet is indicated to treat attention deficit hyperactivity disorder in patients ages 6 years and older.

“We've heard from healthcare providers, ADHD patients and their parents about the need for an affordable alternative to Concerta that works in the same way and at the same time,” Teva Canada senior director of commercial management David Boughner said. “We're pleased to offer patients ACT Methylphenidate ER as a bioequivalent modified release product that allows for a biphasic drug release profile after oral administration.  In addition, the pharmacokinetic parameters mimic the concentration-time release profile of Concerta.”

ADHD is the most common neurodevelopmental disorder, affecting roughly 1-in-20 children, according to Portico, Canada’s mental health and addiction network.

Teva Canada’s generic Concerta will be available in 18-, 27-, 36- and 54-mg tablets. The once-daily drug had a Canadian market size of roughly $175 million for the 12 months ended January 2018, according to IQVIA data.

RELATED TOPICS